Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a new tablet formulation to add to its ZEGERID? family of branded prescription pharmaceutical products. The new formulation is an immediate-release tablet that combines omeprazole, a proton pump inhibitor (PPI), with a mix of buffers.

According to an article published in Archives of Surgery, two non-pharmacological GERD (gastroesophageal reflux disease) treatments seem to be effective in lowering medication use and improving swallowing symptoms as well as the patient's voice. One of the assessed therapies appears to be effective in reducing heartburn and cough. The other one reduces regurgitation. Archives of Surgery is a JAMA/Archives journal.